Synthaverse SA

Synthaverse SA has a debt-to-equity ratio of 0.68, indicating a moderate level of leverage relative to its equity base. The company's liquidity is assessed as medium, with cash and equivalents amounting to PLN 1,673,000, which is significantly lower than its long-term debt of PLN 84,646,000. This suggests potential pressure on liquidity, especially if short-term obligations increase or cash flow from operations declines. In terms of profitability, Synthaverse reported revenue of PLN 42,010,000 in the latest period. While the company's debt-to-equity ratio is below 1, it is still a notable portion of its equity, which may affect its ability to reinvest in growth or withstand economic downturns. The company's financial leverage is moderate, but its net cash position is negative after subtracting total debt, which could limit its flexibility in capital allocation. Synthaverse's revenue is derived from a range of immunotherapy products, including oncological immunotherapy, passive immunotherapy in hepatitis B, and active anti-tuberculosis immunotherapy. The company supplies its products to 50 countries, indicating a broad geographic exposure. However, the input data does not provide specific revenue concentration by region or product segment, so it is unclear if the company is heavily reliant on any particular market or product line. The company's growth trajectory is not explicitly detailed in the input data, but its current revenue of PLN 42,010,000 provides a baseline for future performance. The outlook for the current fiscal year and the next fiscal year is not provided, so it is difficult to assess the company's expected growth rate. However, the company's focus on immunotherapy, a growing segment within the pharmaceutical industry, may offer opportunities for expansion. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash is negative after subtracting total debt, which could be a concern if it needs to raise additional capital. However, the dilution risk is low, suggesting that the company is not expected to issue a significant number of new shares in the near term. The company's capital structure is relatively stable, but it may need to manage its debt levels carefully to maintain financial flexibility. Recent events, such as filings or transcripts, are not provided in the input data, so it is not possible to assess the company's recent performance or strategic direction based on these sources. The company's financial snapshot and risk assessment provide a general overview of its financial health, but more detailed information would be needed to fully understand its recent developments and future prospects.